← Leaderboards
Elie Haddad
University Of California, San Francisco
$1,288,114
Attributed
$4,152,452
Total exposure
2
Grants
1
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $1.9M · FY2014–25$2M$1.5M$1M$500K$0
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$11,561,239 · 3
By mechanism
U54$7,980,817 · 2
R24$3,580,422 · 1
Top collaborators
- Christopher Craig Dvorak7 shared
- Jennifer Maxwell Puck4 shared
- Rebecca Marsh3 shared
- Troy R Torgerson3 shared
- Michael Wagner3 shared
Most similar at University Of California, San Francisco
Same institution · by research overlap
- Christopher Craig Dvorak$1,385,756
- Tracey J. Woodruff$21,216,565
- Youngho Seo$10,977,149
- Lyudmila Popova$5,221,407
- Harry Malech$109,450
Others in their field
Top investigators on “Caring”
- Sonia M Thomas · Research Triangle Institute$700,865,642
- Tracy L Nolen · Research Triangle Institute$474,487,152
- Gerald T Nepom · Benaroya Research Inst At Virginia Mason$305,871,236
- Eric Jeffrey Topol · Cleveland Clinic Lerner Col/Med-Cwru$279,179,778
- Chanza Baytop · Westat, Inc.$271,217,917
- Larry Arthur$256,720,406
Research focus
CaringT-LymphocyteProspectiveFutureGenotypeLate EffectsSamplingGene TherapyEnzyme Replacement TherapyChimerismSevere Combined ImmunodeficiencyDesignSeveritiesB-LymphocytesProtocols DocumentationQuality Of LifePreventBaseImmuneImmunityGrowthImmunologyCellsEvidence Base
Grant awards (12)
Primary Immune Deficiency Treatment Consortium (PIDTC): A resource to drive scientific and clinical advances related to the treatment of inborn errors of immunity$1,743,065
R24 · FY2025 · AI
Primary Immune Deficiency Treatment Consortium (PIDTC): A resource to drive scientific and clinical advances related to the treatment of inborn errors of immunity$21,475
R24 · FY2025 · AI
Primary Immune Deficiency Treatment Consortium (PIDTC): A resource to drive scientific and clinical advances related to the treatment of inborn errors of immunity$1,815,882
R24 · FY2024 · AI
Primary Immune Deficiency Treatment Consortium$1,846,257
U54 · FY2023 · AI
Primary Immune Deficiency Treatment Consortium$1,846,257
U54 · FY2022 · AI
Primary Immune Deficiency Treatment Consortium$1,846,474
U54 · FY2021 · AI
Primary Immune Deficiency Treatment Consortium$1,869,799
U54 · FY2020 · AI
A Retrospective and Cross-Sectional Analysis of Patients Treated for SCID Since January 1,1968$30,521
U54 · FY2018 · AI · contact PI
A Retrospective and Cross-Sectional Analysis of Patients Treated for SCID Since January 1,1968$442,133
U54 · FY2017 · AI · contact PI
A Retrospective and Cross-Sectional Analysis of Patients Treated for SCID Since January 1,1968$29,111
U54 · FY2016 · AI · contact PI
A Retrospective and Cross-Sectional Analysis of Patients Treated for SCID Since January 1,1968$29,111
U54 · FY2015 · AI · contact PI
A Retrospective and Cross-Sectional Analysis of Patients Treated for SCID Since January 1,1968$41,154
U54 · FY2014 · AI · contact PI